# Low-dose NOAC Versus GDMT After LAAO

> **NCT05960721** · NA · RECRUITING · sponsor: **Xijing Hospital** · enrollment: 4220 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Rivaroxaban 15mg
- **DRUG:** Aspirin 100mg
- **DRUG:** Clopidogrel 75mg
- **DRUG:** Rivaroxaban 10mg
- **DRUG:** Rivaroxaban 2.5mg

## Key facts

- **NCT ID:** NCT05960721
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-06
- **Primary completion:** 2025-07-30
- **Final completion:** 2028-07-30
- **Target enrollment:** 4220 (ESTIMATED)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05960721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05960721, "Low-dose NOAC Versus GDMT After LAAO". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05960721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*